IDH1 and neoplasm: In patients with high-risk IDH-mutant tumors (Grade 3 or 4, older age, residual tumor or symptomatic lesion), following initial resection, standard of care typically entails a combination of radiation followed by chemotherapy with either temozolomide or PCV (procarbazine, lomustine and vincristine) (14, 19).